Skip to content
DataLookout
Menu

NCT06385925

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 12 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 30, 2026 to Oct 30, 2027 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 56 words
    • Enrollment increased: 440 → 570 participants
    • Trial sites expanded: 19 → 24 locations
    • Study completion pushed from Apr 30, 2027 to Apr 30, 2028
    • Interventions modified
    • Trial arms changed: 5 → 7
    • Study description expanded, about 1 word
  2. Notable Enrollment target: 150 to 440v6 Show 5 more changesShow less
    • Eligibility criteria expanded, about 64 words
    • Study sites: 6 to 19
    • Interventions: TSN1611 (Drug) to TSN1611 (Drug), TSN1611 (Drug), TSN1611 (Drug), TSN1611 (Drug)
    • Study description expanded, about 85 words
    • Study arms: 2 to 5
  3. Notable Lead sponsor: Tyligand Bioscience (Shanghai) Limited to Tyligand Pharmaceuticals (Suzhou) Limited
    • Site contacts updated at 3 of 6 sites
    v5
  4. Minor Study sites: 3 to 6v4
  5. Minor Start date changed from estimate of Apr 30, 2024 to Apr 29, 2024
    • Site details revised at 1 of 3 sites
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose limiting toxicities (DLTs) in phase 1 part
Timeframe: 21 days
Objective response rate (ORR) in phase 2 part
Timeframe: Up to 3 years
Dose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination Therapy
Timeframe: 28 days
Objective response rate (ORR) in phase 2 part of TSN1611 Combination Therapy
Timeframe: Up to 3 years

Secondary (9)

Adverse events
Area under the plasma concentration-time curve (AUC)
Maximum blood concentrations (Cmax)
Time to maximum blood concentration (Tmax)
Duration of response (DOR)
Show 4 moreShow less
Time to response (TTR)
Disease control rate (DCR)
Progression free survival (PFS)
Overall survival

Arms and interventions

Phase 1a: Dose-finding/evaluation of TSN1611 monotherapyExperimental

The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.

Phase 2: Dose expansion of TSN1611 monotherapyExperimental

Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.

Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort AExperimental

Cohort A: TSN1611 combined with cetuximab treating subjects with advanced solid tumors harboring KRAS G12D mutation:

Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort BExperimental

Cohort B: TSN1611 combined with GnP regimen (i.e., gemcitabine and nab-paclitaxel) treating subjects with advanced PDAC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.

Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort CExperimental

Cohort C: TSN1611 combined with cetuximab and mFOLFOX6 regimen (i.e., fluorouracil, leucovorin, oxaliplatin) treating subjects with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.

Dose of Phase 1b/2 part of TSN1611 combination therapy-Cohort DExperimental

Cohort D: TSN1611 combined with cetuximab and FOLFIRI regimen (i.e., fluorouracil, leucovorin, irinotecan) treating participants with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting. When the enrollment is active for both Cohort C and Cohort D simultaneously, participants could be allocated to either cohort alternatively (e.g., through randomization method), unless contradicted to either cohort.

Phase 1b: Dose-finding/evaluation of TSN1611 monotherapyExperimental

The phase 1b part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.

Drugs: TSN1611

Sites

24 sites in 2 countries

China 21, United States 3